NASDAQ:INMB INmune Bio (INMB) Stock Price, News & Analysis $7.46 -0.22 (-2.86%) Closing price 05/21/2025 04:00 PM EasternExtended Trading$7.54 +0.08 (+1.01%) As of 04:47 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About INmune Bio Stock (NASDAQ:INMB) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get INmune Bio alerts:Sign Up Key Stats Today's Range$7.43▼$7.9250-Day Range$6.73▼$8.8652-Week Range$4.32▼$11.03Volume235,584 shsAverage Volume258,591 shsMarket Capitalization$171.46 millionP/E RatioN/ADividend YieldN/APrice Target$22.80Consensus RatingBuy Company OverviewINmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.Read More… INmune Bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks39th Percentile Overall ScoreINMB MarketRank™: INmune Bio scored higher than 39% of companies evaluated by MarketBeat, and ranked 671st out of 915 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingINmune Bio has received a consensus rating of Buy. The company's average rating score is 3.17, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageINmune Bio has received no research coverage in the past 90 days.Read more about INmune Bio's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for INmune Bio are expected to grow in the coming year, from ($2.24) to ($1.54) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of INmune Bio is -3.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of INmune Bio is -3.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioINmune Bio has a P/B Ratio of 3.60. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about INmune Bio's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted25.37% of the outstanding shares of INmune Bio have been sold short.Short Interest Ratio / Days to CoverINmune Bio has a short interest ratio ("days to cover") of 20.8, which indicates bearish sentiment.Change versus previous monthShort interest in INmune Bio has recently decreased by 2.51%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldINmune Bio does not currently pay a dividend.Dividend GrowthINmune Bio does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted25.37% of the outstanding shares of INmune Bio have been sold short.Short Interest Ratio / Days to CoverINmune Bio has a short interest ratio ("days to cover") of 20.8, which indicates bearish sentiment.Change versus previous monthShort interest in INmune Bio has recently decreased by 2.51%, indicating that investor sentiment is improving. News and Social Media2.3 / 5News SentimentN/A News SentimentINmune Bio has a news sentiment score of 1.09. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.65 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for INmune Bio this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for INMB on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added INmune Bio to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, INmune Bio insiders have not sold or bought any company stock.Percentage Held by Insiders35.20% of the stock of INmune Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 12.72% of the stock of INmune Bio is held by institutions.Read more about INmune Bio's insider trading history. Receive INMB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for INmune Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address INMB Stock News HeadlinesINmune Bio: XPro Trial Readout In Alzheimer's Disease Offers Big OpportunityMay 15, 2025 | seekingalpha.comINmune Bio, Inc. (INMB) Q1 2025 Earnings Call TranscriptMay 10, 2025 | seekingalpha.comThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “secret America” — an America first envisioned by President Harry Truman in 1946, and then classified by the government for decades. May 22, 2025 | Banyan Hill Publishing (Ad)INmune Bio appoints new accounting firmMay 9, 2025 | investing.comINmune Bio, Inc.: INmune Bio Inc. Announces First Quarter 2025 Results and Provides Business UpdateMay 9, 2025 | finanznachrichten.deINmune Bio Inc. Announces First Quarter 2025 Results and Provides Business UpdateMay 8, 2025 | globenewswire.comINmune Bio Inc. to Report First Quarter 2025 Financial Results and Provide Corporate Update on Thursday, May 8thMay 5, 2025 | globenewswire.comINmune Bio Receives Favorable Patentability Opinion for CORDStrom™ Platform TechnologyApril 16, 2025 | markets.businessinsider.comSee More Headlines INMB Stock Analysis - Frequently Asked Questions How have INMB shares performed this year? INmune Bio's stock was trading at $4.67 at the start of the year. Since then, INMB shares have increased by 59.7% and is now trading at $7.46. View the best growth stocks for 2025 here. How were INmune Bio's earnings last quarter? INmune Bio, Inc. (NASDAQ:INMB) announced its earnings results on Thursday, May, 8th. The company reported ($0.43) earnings per share for the quarter, meeting the consensus estimate of ($0.43). The firm had revenue of $0.05 million for the quarter. Read the conference call transcript. Who are INmune Bio's major shareholders? INmune Bio's top institutional shareholders include Raymond James Financial Inc. (1.66%), MAI Capital Management (0.46%), Pekin Hardy Strauss Inc. (0.41%) and Bank of New York Mellon Corp (0.24%). Insiders that own company stock include Raymond Joseph Tesi, David J Moss, Timothy J Schroeder and Scott Juda. View institutional ownership trends. How do I buy shares of INmune Bio? Shares of INMB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of INmune Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that INmune Bio investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Adobe (ADBE), ServiceNow (NOW) and Netflix (NFLX). Company Calendar Last Earnings5/08/2025Today5/21/2025Next Earnings (Estimated)8/07/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:INMB CIK1711754 Webwww.inmunebio.com Phone(858) 964-3720FaxN/AEmployees10Year FoundedN/APrice Target and Rating Average Stock Price Target$22.80 High Stock Price Target$30.00 Low Stock Price Target$18.00 Potential Upside/Downside+205.6%Consensus RatingBuy Rating Score (0-4)3.17 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.93) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-30,010,000.00 Net MarginsN/A Pretax Margin-98,266.67% Return on Equity-117.48% Return on Assets-78.96% Debt Debt-to-Equity RatioN/A Current Ratio2.59 Quick Ratio2.59 Sales & Book Value Annual Sales$50,000.00 Price / Sales3,429.21 Cash FlowN/A Price / Cash FlowN/A Book Value$2.07 per share Price / Book3.60Miscellaneous Outstanding Shares22,984,000Free Float14,367,000Market Cap$171.46 million OptionableOptionable Beta1.63 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:INMB) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredA new financial chapter Porter Stansberry says what happened last week could become the defining legacy of his financial publishing ca...Porter & Company | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s backup plan for AIElon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredExclusive Offer: Target 100% Returns NowBrace yourself–this may come as a shock. It turns out that you may not have to wait decades to turn a small...ProsperityPub | SponsoredPrepare now for May 31 eventPrepare now for May 31 event Circle May 31 on your calendar This man grew up in a trailer in New Mexico. To...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding INmune Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share INmune Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.